ARC-520 clinical trials
Also written ARC-520.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses ARC-520 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ARC-520 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)TerminatedPhase 2Arrowhead PharmaceuticalsNCT02577029Written as ARC-520
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus InfectionTerminatedPhase 2Arrowhead PharmaceuticalsNCT02604212Written as ARC-520
- A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) InfectionTerminatedPhase 2Arrowhead PharmaceuticalsNCT02065336Written as ARC-520
- Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) InfectionTerminatedPhase 2Arrowhead PharmaceuticalsNCT02738008Written as ARC-520 Injection
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) InfectionTerminatedPhase 2Arrowhead PharmaceuticalsNCT02604199Written as ARC-520 Injection
- Safety and Tolerability Study of ARC-520 in Healthy VolunteersCompletedPhase 1Arrowhead PharmaceuticalsNCT01872065Written as ARC-520
- Study of ARC-520 in Patient With Chronic Hepatitis B VirusWithdrawnPhase 2Arrowhead PharmaceuticalsNCT02349126Written as ARC-520 Injection
- Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B VirusTerminatedPhase 2Arrowhead PharmaceuticalsNCT02452528Written as ARC-520
Given beside what is tested · 1 — ARC-520 is usual care or a partner of the new treatment
Codes
What other systems call ARC-520 · ClinicalTrials.gg INT001621
- MeSH (NLM) C000717093ARC-520One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000717093 | ARC-520 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.